Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Stock Has Consensus Price Target of $23.36

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) has been given a consensus recommendation of “Moderate Buy” by the seventeen analysts that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $23.36.

Several equities analysts have commented on CMPS shares. Wells Fargo & Company assumed coverage on Compass Pathways in a research report on Monday, July 27th. They issued an “equal weight” rating and a $13.00 target price for the company. Royal Bank Of Canada reduced their price target on Compass Pathways from $22.00 to $21.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. B. Riley Financial boosted their price target on Compass Pathways from $17.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Oppenheimer reaffirmed an “outperform” rating on shares of Compass Pathways in a research note on Wednesday, August 5th. Finally, Compass Point set a $25.00 price objective on shares of Compass Pathways in a report on Tuesday, July 7th.

Institutional Trading of Compass Pathways

Several institutional investors have recently modified their holdings of the business. North Star Investment Management Corp. raised its position in Compass Pathways by 23.9% during the 3rd quarter. North Star Investment Management Corp. now owns 9,317 shares of the company’s stock worth $116,000 after purchasing an additional 1,800 shares during the last quarter. EverSource Wealth Advisors LLC lifted its holdings in Compass Pathways by 67.7% during the 1st quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock worth $26,000 after buying an additional 1,920 shares during the period. WINTON GROUP Ltd lifted its holdings in Compass Pathways by 20.1% during the 2nd quarter. WINTON GROUP Ltd now owns 17,900 shares of the company’s stock worth $253,000 after buying an additional 3,000 shares during the period. Ancora Advisors LLC acquired a new position in Compass Pathways during the 2nd quarter worth about $43,000. Finally, China Universal Asset Management Co. Ltd. grew its position in shares of Compass Pathways by 15.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 24,432 shares of the company’s stock valued at $317,000 after buying an additional 3,249 shares during the last quarter. Institutional investors own 46.19% of the company’s stock.

Compass Pathways Stock Up 4.0%

Shares of CMPS opened at $12.28 on Monday. Compass Pathways has a 52 week low of $4.88 and a 52 week high of $15.87. The stock has a market capitalization of $1.70 billion, a price-to-earnings ratio of -2.66 and a beta of 2.55. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.30 and a current ratio of 1.30. The stock has a fifty day moving average of $12.99 and a 200-day moving average of $10.33.

Compass Pathways (NASDAQ:CMPS) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.88) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($1.49). As a group, sell-side analysts anticipate that Compass Pathways will post -1.26 earnings per share for the current fiscal year.

Compass Pathways Company Profile

Compass Pathways plc is a biotechnology company developing novel treatments for mental health conditions. The company’s lead investigational product is COMP360, a proprietary formulation of synthetic psilocybin administered with psychological support in a controlled clinical setting.

Compass Pathways has focused primarily on treatment-resistant depression, a condition in which patients do not respond adequately to existing therapies. Its research programs have included mid- and late-stage clinical trials designed to evaluate the safety and effectiveness of COMP360, as well as studies exploring its potential use in other mental health disorders.

Founded in 2016 and headquartered in London, Compass Pathways conducts research and clinical development activities across the United States, the United Kingdom and other international markets.